{"id":"https://openalex.org/W2270599714","doi":"https://doi.org/10.1200/jco.2009.27.15_suppl.3536","title":"Phase I first-in-human study of the polo-like kinase-1 selective inhibitor, GSK461364, in patients with advanced solid tumors","display_name":"Phase I first-in-human study of the polo-like kinase-1 selective inhibitor, GSK461364, in patients with advanced solid tumors","publication_year":2009,"publication_date":"2009-05-20","ids":{"openalex":"https://openalex.org/W2270599714","doi":"https://doi.org/10.1200/jco.2009.27.15_suppl.3536","mag":"2270599714"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2009.27.15_suppl.3536","doi":"https://doi.org/10.1200/jco.2009.27.15_suppl.3536","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2009.27.15_suppl.3536","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5072116005","display_name":"David Olmos","orcid":"https://orcid.org/0000-0002-7003-4826","observed_orcids":["https://orcid.org/0000-0002-7003-4826"]},"institutions":[{"id":"https://openalex.org/I1325846038","display_name":"Royal Marsden NHS Foundation Trust","ror":"https://ror.org/0008wzh48","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I1325846038"]},{"id":"https://openalex.org/I153355300","display_name":"Imperial College Healthcare NHS Trust","ror":"https://ror.org/056ffv270","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I153355300"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"D. Olmos","raw_affiliation_strings":["The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom; GlaxoSmithKline, Research Triangle Park, NC; Imperial College Healthcare NHS Trust, London, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom; GlaxoSmithKline, Research Triangle Park, NC; Imperial College Healthcare NHS Trust, London, United Kingdom","institution_ids":["https://openalex.org/I1325846038","https://openalex.org/I153355300"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001344340","display_name":"Alicia Jones Allred","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1325846038","display_name":"Royal Marsden NHS Foundation Trust","ror":"https://ror.org/0008wzh48","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I1325846038"]},{"id":"https://openalex.org/I153355300","display_name":"Imperial College Healthcare NHS Trust","ror":"https://ror.org/056ffv270","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I153355300"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"A. Allred","raw_affiliation_strings":["The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom; GlaxoSmithKline, Research Triangle Park, NC; Imperial College Healthcare NHS Trust, London, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom; GlaxoSmithKline, Research Triangle Park, NC; Imperial College Healthcare NHS Trust, London, United Kingdom","institution_ids":["https://openalex.org/I1325846038","https://openalex.org/I153355300"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5007167001","display_name":"Rohini Sharma","orcid":"https://orcid.org/0000-0003-2441-549X","observed_orcids":["https://orcid.org/0000-0003-2441-549X"]},"institutions":[{"id":"https://openalex.org/I1325846038","display_name":"Royal Marsden NHS Foundation Trust","ror":"https://ror.org/0008wzh48","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I1325846038"]},{"id":"https://openalex.org/I153355300","display_name":"Imperial College Healthcare NHS Trust","ror":"https://ror.org/056ffv270","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I153355300"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"R. Sharma","raw_affiliation_strings":["The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom; GlaxoSmithKline, Research Triangle Park, NC; Imperial College Healthcare NHS Trust, London, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom; GlaxoSmithKline, Research Triangle Park, NC; Imperial College Healthcare NHS Trust, London, United Kingdom","institution_ids":["https://openalex.org/I1325846038","https://openalex.org/I153355300"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5017043037","display_name":"Andre Tesainer Brunetto","orcid":"https://orcid.org/0000-0002-7958-1279","observed_orcids":["https://orcid.org/0000-0002-7958-1279"]},"institutions":[{"id":"https://openalex.org/I1325846038","display_name":"Royal Marsden NHS Foundation Trust","ror":"https://ror.org/0008wzh48","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I1325846038"]},{"id":"https://openalex.org/I153355300","display_name":"Imperial College Healthcare NHS Trust","ror":"https://ror.org/056ffv270","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I153355300"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"A. Brunetto","raw_affiliation_strings":["The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom; GlaxoSmithKline, Research Triangle Park, NC; Imperial College Healthcare NHS Trust, London, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom; GlaxoSmithKline, Research Triangle Park, NC; Imperial College Healthcare NHS Trust, London, United Kingdom","institution_ids":["https://openalex.org/I1325846038","https://openalex.org/I153355300"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001448137","display_name":"Deborah Ann Smith","orcid":"https://orcid.org/0000-0003-1118-2041","observed_orcids":["https://orcid.org/0000-0003-1118-2041"]},"institutions":[{"id":"https://openalex.org/I1325846038","display_name":"Royal Marsden NHS Foundation Trust","ror":"https://ror.org/0008wzh48","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I1325846038"]},{"id":"https://openalex.org/I153355300","display_name":"Imperial College Healthcare NHS Trust","ror":"https://ror.org/056ffv270","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I153355300"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"D. Smith","raw_affiliation_strings":["The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom; GlaxoSmithKline, Research Triangle Park, NC; Imperial College Healthcare NHS Trust, London, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom; GlaxoSmithKline, Research Triangle Park, NC; Imperial College Healthcare NHS Trust, London, United Kingdom","institution_ids":["https://openalex.org/I1325846038","https://openalex.org/I153355300"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110482434","display_name":"Sharon Cornell Murray","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1325846038","display_name":"Royal Marsden NHS Foundation Trust","ror":"https://ror.org/0008wzh48","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I1325846038"]},{"id":"https://openalex.org/I153355300","display_name":"Imperial College Healthcare NHS Trust","ror":"https://ror.org/056ffv270","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I153355300"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"S. Murray","raw_affiliation_strings":["The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom; GlaxoSmithKline, Research Triangle Park, NC; Imperial College Healthcare NHS Trust, London, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom; GlaxoSmithKline, Research Triangle Park, NC; Imperial College Healthcare NHS Trust, London, United Kingdom","institution_ids":["https://openalex.org/I1325846038","https://openalex.org/I153355300"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022441963","display_name":"Douglas S. Barker","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1325846038","display_name":"Royal Marsden NHS Foundation Trust","ror":"https://ror.org/0008wzh48","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I1325846038"]},{"id":"https://openalex.org/I153355300","display_name":"Imperial College Healthcare NHS Trust","ror":"https://ror.org/056ffv270","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I153355300"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"D. Barker","raw_affiliation_strings":["The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom; GlaxoSmithKline, Research Triangle Park, NC; Imperial College Healthcare NHS Trust, London, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom; GlaxoSmithKline, Research Triangle Park, NC; Imperial College Healthcare NHS Trust, London, United Kingdom","institution_ids":["https://openalex.org/I1325846038","https://openalex.org/I153355300"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051272264","display_name":"Anne B. Taegtmeyer","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1325846038","display_name":"Royal Marsden NHS Foundation Trust","ror":"https://ror.org/0008wzh48","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I1325846038"]},{"id":"https://openalex.org/I153355300","display_name":"Imperial College Healthcare NHS Trust","ror":"https://ror.org/056ffv270","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I153355300"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"A. Taegtmeyer","raw_affiliation_strings":["The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom; GlaxoSmithKline, Research Triangle Park, NC; Imperial College Healthcare NHS Trust, London, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom; GlaxoSmithKline, Research Triangle Park, NC; Imperial College Healthcare NHS Trust, London, United Kingdom","institution_ids":["https://openalex.org/I1325846038","https://openalex.org/I153355300"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072378199","display_name":"Johann Sebastian De Bono","orcid":"https://orcid.org/0000-0002-2034-595X","observed_orcids":["https://orcid.org/0000-0002-2034-595X"]},"institutions":[{"id":"https://openalex.org/I1325846038","display_name":"Royal Marsden NHS Foundation Trust","ror":"https://ror.org/0008wzh48","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I1325846038"]},{"id":"https://openalex.org/I153355300","display_name":"Imperial College Healthcare NHS Trust","ror":"https://ror.org/056ffv270","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I153355300"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"J. de Bono","raw_affiliation_strings":["The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom; GlaxoSmithKline, Research Triangle Park, NC; Imperial College Healthcare NHS Trust, London, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom; GlaxoSmithKline, Research Triangle Park, NC; Imperial College Healthcare NHS Trust, London, United Kingdom","institution_ids":["https://openalex.org/I1325846038","https://openalex.org/I153355300"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5068550336","display_name":"Sarah Patricia Blagden","orcid":"https://orcid.org/0000-0001-8783-3491","observed_orcids":["https://orcid.org/0000-0001-8783-3491"]},"institutions":[{"id":"https://openalex.org/I1325846038","display_name":"Royal Marsden NHS Foundation Trust","ror":"https://ror.org/0008wzh48","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I1325846038"]},{"id":"https://openalex.org/I153355300","display_name":"Imperial College Healthcare NHS Trust","ror":"https://ror.org/056ffv270","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I153355300"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"S. Blagden","raw_affiliation_strings":["The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom; GlaxoSmithKline, Research Triangle Park, NC; Imperial College Healthcare NHS Trust, London, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom; GlaxoSmithKline, Research Triangle Park, NC; Imperial College Healthcare NHS Trust, London, United Kingdom","institution_ids":["https://openalex.org/I1325846038","https://openalex.org/I153355300"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":22,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"27","issue":"15_suppl","first_page":"3536","last_page":"3536"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10492","display_name":"Microtubule and mitosis dynamics","score":0.9868000149726868,"subfield":{"id":"https://openalex.org/subfields/1307","display_name":"Cell Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10492","display_name":"Microtubule and mitosis dynamics","score":0.9868000149726868,"subfield":{"id":"https://openalex.org/subfields/1307","display_name":"Cell Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11752","display_name":"Cancer Treatment and Pharmacology","score":0.004000000189989805,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10274","display_name":"Synthesis and biological activity","score":0.00139999995008111,"subfield":{"id":"https://openalex.org/subfields/1605","display_name":"Organic Chemistry"},"field":{"id":"https://openalex.org/fields/16","display_name":"Chemistry"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/polo-like-kinase-1-inhibitor","display_name":"polo-like kinase 1 inhibitor","score":0.8040000200271606},{"id":"https://openalex.org/keywords/plk1","display_name":"PLK1","score":0.7089999914169312},{"id":"https://openalex.org/keywords/advanced-solid-tumors","display_name":"advanced solid tumors","score":0.9179999828338623},{"id":"https://openalex.org/keywords/relapsed-refractory-cancer","display_name":"relapsed/refractory cancer","score":0.8840000033378601},{"id":"https://openalex.org/keywords/maximum-tolerated-dose","display_name":"maximum tolerated dose","score":0.9549999833106995},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.9480000138282776},{"id":"https://openalex.org/keywords/sepsis","display_name":"sepsis","score":0.843999981880188},{"id":"https://openalex.org/keywords/pulmonary-embolism","display_name":"pulmonary embolism","score":0.9890000224113464},{"id":"https://openalex.org/keywords/neutropenia","display_name":"neutropenia","score":0.9559999704360962},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.7990000247955322},{"id":"https://openalex.org/keywords/anticancer-activity","display_name":"anticancer activity","score":0.7179999947547913},{"id":"https://openalex.org/keywords/intravenous-administration","display_name":"intravenous administration","score":0.3779999911785126}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8988577127456665},{"id":"https://openalex.org/C2777063308","wikidata":"https://www.wikidata.org/wiki/Q1435822","display_name":"Neutropenia","level":3,"score":0.7509733438491821},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.5296019315719604},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5020434856414795},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.49301406741142273},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4841788113117218},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.477438747882843},{"id":"https://openalex.org/C2778850193","wikidata":"https://www.wikidata.org/wiki/Q3775974","display_name":"Febrile neutropenia","level":4,"score":0.4653639793395996},{"id":"https://openalex.org/C2780852908","wikidata":"https://www.wikidata.org/wiki/Q127076","display_name":"Vomiting","level":2,"score":0.46058812737464905},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3429601788520813},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.27568620443344116}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2009.27.15_suppl.3536","doi":"https://doi.org/10.1200/jco.2009.27.15_suppl.3536","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2009.27.15_suppl.3536","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2102126248","https://openalex.org/W2507926833","https://openalex.org/W2049894179","https://openalex.org/W2737358433","https://openalex.org/W2133350827","https://openalex.org/W2753828943","https://openalex.org/W1581801730","https://openalex.org/W2501864253","https://openalex.org/W2168282983","https://openalex.org/W1799713393"],"abstract_inverted_index":{"3536":[0],"Background:":[1],"Polo-like":[2],"kinase-1":[3],"(Plk1),":[4],"part":[5],"of":[6,9,40,65,75,82,113,120,281,345],"a":[7,34,86,224,258,343],"family":[8],"highly":[10],"conserved":[11],"serine-threonine":[12],"kinases,":[13],"has":[14,362,377,384],"multiple":[15],"roles":[16],"in":[17,28,48,51,157,181,192,209,350,365,374],"mitotic":[18,346],"progression,":[19],"is":[20,33],"over-expressed":[21],"and":[22,36,50,67,110,149,173,204,230,245,267,284,312,325,338],"also":[23],"associated":[24],"with":[25,44,57,62,223,257],"poor":[26],"prognosis":[27],"some":[29],"tumor":[30,352],"types.":[31],"GSK461364":[32,83],"potent":[35],"selective":[37],"ATP-competitive":[38],"inhibitor":[39],"Plk1":[41],"(Ki":[42],"2.2nM)":[43],"demonstrated":[45],"antiproliferative":[46],"activity":[47],"vitro":[49],"vivo.":[52],"Methods:":[53],"Adult":[54],"patients":[55,77],"(pts)":[56],"relapsed/refractory":[58],"advanced":[59],"solid":[60],"tumors":[61],"performance":[63],"status":[64],"0\u20132":[66],"adequate":[68],"organ":[69],"function":[70],"were":[71,102,130,155,179,188,228,262,287,327,333],"eligible.":[72],"Sequential":[73],"cohorts":[74],"2\u20136":[76],"each":[78],"received":[79],"escalating":[80],"doses":[81],"administered":[84],"as":[85],"4h":[87],"intravenous":[88],"infusion":[89,313],"(Schedule":[90],"[Sch]":[91],"1:":[92],"D1,8,15":[93],"q28":[94],"or":[95],"Sch":[96,158,182,193,210,218,254,283],"2:":[97],"D1,2,8,9,15,16":[98],"q28).":[99],"Primary":[100],"objectives":[101,116],"to":[103],"determine":[104],"the":[105],"maximum":[106,225,259],"tolerated":[107],"dose":[108,133,161,285],"(MTD)":[109],"pharmacokinetics":[111],"(PK)":[112],"GSK461364.":[114],"Secondary":[115],"included":[117],"preliminary":[118],"evaluation":[119],"anti-tumor":[121],"activity.":[122],"Results:":[123],"27":[124],"pts":[125],"(20":[126],"male,":[127],"7":[128],"female)":[129],"evaluated.":[131],"Four":[132],"levels,":[134,162],"50mg":[135],"(n":[136,141,146,152,165,170,176,289,293,297,301,305,309,316],"=":[137,142,147,153,166,171,177,234,251,272,290,294,298,302,306,310,317],"2),":[138,167,235],"100":[139,174,214],"mg":[140,145,151,164,169,175,197,215],"3),":[143],"150":[144],"3)":[148],"225":[150,196],"8)":[154],"evaluated":[156,180],"1.":[159],"Three":[160],"25":[163],"50":[168],"2)":[172],"7)":[178],"2.":[183],"Dose-limiting":[184],"toxicities":[185],"(DLTs)":[186],"observed":[187,364],"Gr":[189,199,205],"4":[190,200,206],"sepsis,":[191],"1":[194,219],"at":[195,213,380],"dose,":[198],"pulmonary":[201],"embolism":[202],"(PE)":[203],"neutropenia":[207],">7d":[208],"2,":[211],"both":[212],"dose.":[216,358],"Other":[217,253],"adverse":[220,277],"events":[221,278],"(AEs)":[222,279],"grade":[226,260],"\u22653":[227,261],"fatigue":[229,292],"anemia":[231,300],"(both,":[232],"n":[233,250,271],"pleuritic":[236],"pain,":[237,239],"pelvic":[238],"abdominal":[240],"discomfort,":[241],"constipation,":[242],"vomiting,":[243],"neutropenia,":[244],"deep":[246],"vein":[247],"thrombosis":[248],"(all,":[249],"1).":[252,273],"2":[255,366],"AEs":[256],"PE,":[263],"renal":[264],"failure,":[265],"thrombocytopenia,":[266],"catheter-related":[268],"infection":[269],"(all":[270],"The":[274],"most":[275],"common":[276],"regardless":[280],"attribution,":[282],"level":[286],"phlebitis":[288],"9),":[291,295],"nausea":[296],"7),":[299],"6),":[303,307,311],"anorexia":[304],"diarrhea":[308],"site":[314],"reaction":[315],"5).":[318],"Preliminary":[319],"PK":[320],"data":[321],"indicate":[322],"that":[323],"AUC":[324],"Cmax":[326],"proportional":[328],"across":[329],"doses;":[330],"mean":[331],"values":[332],"CLs":[334],"\u223c72\u201385L/hr,":[335],"Vss":[336],"\u223c550\u20131200L":[337],"t1/2":[339],"\u223c11.5hr.":[340],"Phospho-histone":[341],"H3,":[342],"marker":[344],"arrest,":[347],"was":[348],"detected,":[349],"circulating":[351],"cells,":[353],"24":[354],"hrs":[355],"after":[356],"first":[357],"Stable":[359],"disease":[360],">5m":[361],"been":[363,378,387],"esophageal":[367],"cancer":[368],"pts.":[369],"Conclusions:":[370],"Dose":[371],"escalation":[372],"continues":[373],"Sch1,":[375],"Sch2":[376],"expanded":[379],"75mg.":[381],"An":[382],"MTD":[383],"not":[385],"yet":[386],"defined.":[388],"[Table:":[389],"see":[390],"text]":[391]},"counts_by_year":[{"year":2023,"cited_by_count":4},{"year":2017,"cited_by_count":1},{"year":2014,"cited_by_count":1},{"year":2012,"cited_by_count":5}],"updated_date":"2026-09-22T06:50:58.402377","created_date":"2016-06-24T00:00:00"}